Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis
Journal of Clinical Investigation, ISSN: 0021-9738, Vol: 114, Issue: 3, Page: 438-446
2004
- 973Citations
- 282Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations973
- Citation Indexes969
- 969
- CrossRef767
- Patent Family Citations3
- Patent Families3
- Policy Citations1
- Policy Citation1
- Captures282
- Readers282
- 198
- 84
- Mentions1
- References1
- Wikipedia1
Article Description
Previous reports have identified a circulating pool of CD45 collagen I CXCR4 (CD45Col I CXCR4) cells, termed fibrocytes, that traffic to areas of fibrosis. No studies have demonstrated that these cells actually contribute to fibrosis, however. Pulmonary fibrosis was originally thought to be mediated solely by resident lung fibroblasts. Here we show that a population of human CD45Col ICXCR4 circulating fibrocytes migrates in response to CXCL12 and traffics to the lungs in a murine model of bleomycin-induced pulmonary fibrosis. Next, we demonstrated that murine CD45Col ICXCR4 fibrocytes also traffic to the lungs in response to a bleomycin challenge. Maximal intrapulmonary recruitment of CD45Col ICXCR4 fibrocytes directly correlated with increased collagen deposition in the lungs. Treatment of bleomycin-exposed animals with specific neutralizing anti-CXCL12 Ab's inhibited intrapulmonary recruitment of CD45Col I CXCR4 circulating fibrocytes and attenuated lung fibrosis. Thus, our results demonstrate, we believe for the first time, that circulating fibrocytes contribute to the pathogenesis of pulmonary fibrosis.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=4043055316&origin=inward; http://dx.doi.org/10.1172/jci200420997; http://www.ncbi.nlm.nih.gov/pubmed/15286810; http://dx.doi.org/10.1172/jci20997; http://www.jci.org/articles/view/20997; https://dx.doi.org/10.1172/jci20997; https://www.jci.org/articles/view/20997; https://dx.doi.org/10.1172/jci200420997
American Society for Clinical Investigation
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know